Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Bipulendu Jena"'
Autor:
Harjeet Singh, Matthew J Figliola, Margaret J Dawson, Simon Olivares, Ling Zhang, Ge Yang, Sourindra Maiti, Pallavi Manuri, Vladimir Senyukov, Bipulendu Jena, Partow Kebriaei, Richard E Champlin, Helen Huls, Laurence J N Cooper
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e64138 (2013)
Adoptive transfer of T cells expressing a CD19-specific chimeric antigen receptor (CAR) is being evaluated in multiple clinical trials. Our current approach to adoptive immunotherapy is based on a second generation CAR (designated CD19RCD28) that sig
Externí odkaz:
https://doaj.org/article/9e74176212bd40a58bea38aeed27eae3
Autor:
Bipulendu Jena, Sourindra Maiti, Helen Huls, Harjeet Singh, Dean A Lee, Richard E Champlin, Laurence J N Cooper
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e57838 (2013)
Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-tumor responses. Most infuse T cells genetically modified to express a chimeric antigen receptor (CAR) with specificity derived from the scFv region of a CD19-sp
Externí odkaz:
https://doaj.org/article/88ac35af49654cb9ab652e8bcc808407
Autor:
Simon Olivares, David Rushworth, Dean A. Lee, Sourindra Maiti, Jianliang Dai, Neima Briggs, Bipulendu Jena, Srinivas S. Somanchi, Laurence J.N. Cooper
Publikováno v:
Journal of Immunotherapy. 37:204-213
T cells genetically modified to stably express immunoreceptors are being assessed for therapeutic potential in clinical trials. T cells expressing a chimeric antigen receptor (CAR) are endowed with a new specificity to target tumor-associated antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4462377c63e57f6cfb77aa507b267640
https://doi.org/10.1097/cji.0000000000000032
https://doi.org/10.1097/cji.0000000000000032
Autor:
Claude Sportes, Dennis D. Hickstein, Brenna Hansen, Irina Maric, William G. Telford, Ronald E. Gress, Michael R. Bishop, Sadik H. Kassim, Daniel H. Fowler, Bipulendu Jena, Steven A. Rosenberg, Mark E. Dudley, Jennifer Wilder, Bazetta Blacklock-Schuver, Nancy M. Hardy, Robert O. Carpenter, Frances T. Hakim, Juan Gea-Banacloche, Steven Z. Pavletic, Jeremy J. Rose, James N. Kochenderfer, Anthony R. Mato, David Halverson, Steven A. Feldman
Publikováno v:
Blood. 122:4129-4139
New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric antigen receptor (CAR) ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09745faf3f107a0dbc14be407a9c9c8c
https://doi.org/10.1182/blood-2013-08-519413
https://doi.org/10.1182/blood-2013-08-519413
Autor:
Qianxing Mo, Leonid S. Metelitsa, Amy N. Courtney, Bipulendu Jena, Laurence J.N. Cooper, Linjie Guo, Xin Xu, Ekaterina Marinova, Andras Heczey, Daofeng Liu, Gianpietro Dotti, Gengwen Tian, Hiroki Torikai
Vα24-invariant natural killer T cells (NKTs) localize to tumors and have inherent antitumor properties, making them attractive chimeric antigen receptor (CAR) carriers for redirected cancer immunotherapy. However, clinical application of CAR-NKTs ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19eb77d4820ae00936f84f37d2917b06
https://europepmc.org/articles/PMC4887157/
https://europepmc.org/articles/PMC4887157/
Autor:
Bipulendu Jena, Partow Kebriaei, Laurence J.N. Cooper, Chitra Hosing, Elizabeth J. Shpall, William G. Wierda
Publikováno v:
Current Hematologic Malignancy Reports. 8:60-70
Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741d67aab5b1079b7551bdc1e2c6a9c2
https://doi.org/10.1007/s11899-012-0145-y
https://doi.org/10.1007/s11899-012-0145-y
Publikováno v:
Aquaculture Research. 44:1901-1911
Vitellogenin was purified from the serum of 17-β estradiol (E2)-induced juvenile Catla catla using a simple two-step purification procedure i.e. selective chemical precipitation followed by gel filtration chromatography. Purified protein migrated as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bbe78c9d0fdd21de41595f05d415e87
https://doi.org/10.1111/j.1365-2109.2012.03195.x
https://doi.org/10.1111/j.1365-2109.2012.03195.x
Publikováno v:
Current hematologic malignancy reports. 9(1)
T cells that have been genetically modified, activated, and propagated ex vivo can be infused to control tumor progression in patients who are refractory to conventional treatments. Early-phase clinical trials demonstrate that the tumor-associated an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012966c80c4155d92b35ca7fe578e9ea
https://pubmed.ncbi.nlm.nih.gov/24488441
https://pubmed.ncbi.nlm.nih.gov/24488441
Autor:
Gengwen Tian, Amy N Courtney, Bipulendu Jena, Andras Heczey, Daofeng Liu, Ekaterina Marinova, Linjie Guo, Xin Xu, Gianpietro Dotti, Laurence J Cooper, Leonid S Metelitsa
Publikováno v:
The Journal of Immunology. 196:142.1-142.1
Va24-invariant Natural Killer T cells (NKTs) have potent antitumor properties and are being developed for cellular immunotherapy of cancer. Such therapy requires extensive ex vivo expansion of primary NKTs while preserving their longevity and functio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::577418914395fea1b4ed9bf190b6efad
https://doi.org/10.4049/jimmunol.196.supp.142.1
https://doi.org/10.4049/jimmunol.196.supp.142.1
Autor:
Bipulendu Jena, Hiroaki Taguchi, Ana Beatriz Korngold, Laurence J.N. Cooper, Aleksandra Nowicka, Helen Huls
Publikováno v:
Cancer Immunology Research. 4:A179-A179
Success of T-cell based immunotherapy depends largely on exogenous modification and propagation of patient or donor derived T cells. The conventional paradigm is to stimulate primary T cells cross-linking endogenous CD3-complex with a monoclonal anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4e397b389f50c955e84c2a20835c5af
https://doi.org/10.1158/2326-6074.cricimteatiaacr15-a179
https://doi.org/10.1158/2326-6074.cricimteatiaacr15-a179